3681.HK Stock Analysis
36
Uncovered
SinoMab BioScience Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
SinoMab Bioscience Ltd. operates as a clinical stage biopharmaceutical company. The company employs 296 full-time employees The company went IPO on 2019-11-12. The firm primarily develops mAb-based biologics and new chemical entities (NCE). The Company’s product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The firm is developing drugs for the treatment of RA, systemic lupus erythematosus (SLE), asthma, pemphigus, sjogren’s syndrome (SS) and other immunological diseases.